Thematics Asset Management Lowers Holdings in CryoPort, Inc. $CYRX

Thematics Asset Management trimmed its stake in shares of CryoPort, Inc. (NASDAQ:CYRX) by 14.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,638,623 shares of the company’s stock after selling 276,262 shares during the period. Thematics Asset Management owned about 3.27% of CryoPort worth $15,534,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of CYRX. UBS Group AG boosted its position in CryoPort by 112.7% in the 3rd quarter. UBS Group AG now owns 1,331,521 shares of the company’s stock worth $12,623,000 after purchasing an additional 705,649 shares in the last quarter. Kennedy Capital Management LLC purchased a new position in shares of CryoPort during the 2nd quarter valued at approximately $4,084,000. Assenagon Asset Management S.A. lifted its stake in shares of CryoPort by 37.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,498,774 shares of the company’s stock valued at $14,208,000 after purchasing an additional 408,263 shares during the period. Norges Bank acquired a new position in shares of CryoPort in the 2nd quarter valued at $1,624,000. Finally, AQR Capital Management LLC boosted its holdings in CryoPort by 285.5% during the first quarter. AQR Capital Management LLC now owns 262,596 shares of the company’s stock worth $1,597,000 after buying an additional 194,482 shares in the last quarter. 92.90% of the stock is currently owned by hedge funds and other institutional investors.

CryoPort Price Performance

Shares of NASDAQ:CYRX opened at $7.82 on Friday. The business’s 50 day moving average price is $9.26 and its 200-day moving average price is $9.36. CryoPort, Inc. has a 1 year low of $4.63 and a 1 year high of $11.45. The firm has a market capitalization of $389.91 million, a price-to-earnings ratio of 5.92 and a beta of 1.69.

CryoPort (NASDAQ:CYRX) last issued its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.02). The company had revenue of $45.45 million during the quarter, compared to analysts’ expectations of $42.92 million. CryoPort had a negative return on equity of 8.22% and a net margin of 42.35%. On average, sell-side analysts expect that CryoPort, Inc. will post -0.99 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CYRX has been the topic of several analyst reports. Wall Street Zen lowered shares of CryoPort from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Weiss Ratings reiterated a “sell (d+)” rating on shares of CryoPort in a research report on Monday, December 29th. Finally, Needham & Company LLC raised their target price on CryoPort from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $12.94.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.